Get Support

Learn Mode

BAX - Baxter International Inc

55

$16.80

$1.00 (6.329%)

At market close

$16.97

$0.17 (0.985%)

Pre Market 4/1/26, 10:44 AM

2.23/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

BAX

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$8.64B

Industry

Health Care

EPS (TTM)

-$1.86

P/E (TTM)

0.00

Div & Yield

$0.04 (0.24%)

FCF Payout Ratio

6.20%

P/S (TTM)

0.77

P/B

1.41

Diluted Shares

513.00M

Ex-Dividend

2026-02-27

Next Earnings

04-30

Forward P/E

8.32

Payout Ratio

0.00%

P/FCF (TTM)

26.03

FCF Yield

3.84%

Earnings Yield

-11.07%

52 Week Range

Score Card

Explore Scores Tab

2.23

Bad

Baxter International Inc has seen its revenue decline by -12.54% over the past year, which means the company is losing sales/customers. Also, it has an operating margin of 3.78%, which suggests the operations are not very profitable.

Valuation Model

Key Score

3.00

Average

Management

5.00

Very Good

Growth

4.00

Good

Profitability

2.00

Bad

Fin. Health

5.00

Very Good

Dividends

5.00

Very Good

Analyst

2.00

Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-26 16:10:06

Form ARS

Unknown Form Type

Filed on 2026-03-23 09:02:38

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-03-23 08:52:56

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-03-23 08:51:59

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-19 16:45:33

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-16 08:49:18

Form PRE 14A

Unknown Form Type

Filed on 2026-03-13 08:48:10

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 16:08:56

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 16:07:58

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 16:07:11

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 16:06:14

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 16:05:18

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$42.35

152.1%

Avg:

$21.95

30.7%

Low:

$15.15

-9.8%

(% change is relative to the current stock price: $16.80)

Analyst Recommendations

Go to Analyst Tab

3.23

Average

5%

Strong Buy (1)

18%

Buy (4)

73%

Hold (16)

5%

Sell (1)

0%

Strong Sell (0)

About

Website
https://www.baxter.com/
Address
One Baxter Parkway, Deerfield ILLINOIS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=10456

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. The company is headquartered in Deerfield, Illinois and currently employs 37,500 full-time employees. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. The company provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.

IPO Date

1961-05-15

Industry

Health Care

Total Employees

37,500

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Health Care Equipment & Supplies

GICS Sub

Health Care Equipment

GICS Sector

Health Care

GICS Group

Health Care Equipment & Services